Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION

PMA Number: P970029 · 2022-09-01

Decision Date2022-09-01
PMA NumberP970029
Product CodeMNO
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeCV

Device Summary

SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION is the device name listed in this FDA PMA record. The listed applicant is Cryolife, Inc.. It received FDA Premarket Approval (PMA) on 2022-09-01 under PMA number P970029. The device is classified under FDA product code MNO. It was reviewed by the CV advisory panel. This device is classified as Class III by the FDA. Class III devices subject to the most stringent regulatory controls. These devices generally require premarket approval (PMA) because they support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA. The device falls under the medical specialty of U. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness. PMA is generally required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.

Frequently Asked Questions

What is SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION?

SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION is a medical device that received FDA Premarket Approval (PMA) on 2022-09-01. The listed applicant is Cryolife, Inc.. The PMA number is P970029.

When did SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION receive FDA PMA approval?

SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION received FDA PMA approval on 2022-09-01, under PMA number P970029.

Who is the listed applicant for SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION?

The FDA PMA record lists Cryolife, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the difference between PMA and 510(k)?

PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.

What is the FDA product code for SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION?

The FDA product code for SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION is MNO.

What FDA device class is SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION?

SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION is classified as Class III by the FDA.

Other records listing Cryolife, Inc. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.